Company intelligence / Profile preview
NeuGATE Theranostics
Houston, Texas, United Statespmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- Phase 1
01
Overview
NeuGATE Theranostics is developing NG101m, an oral small molecule adjuvant therapy intended to be used alongside standard-of-care temozolomide and radiation for newly diagnosed glioblastoma multiforme. The first-in-human trial is planned but not yet recruiting as of early/mid 2025. No published clinical results are available.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
RhoTauPharma lists NeuGATE Theranostics among its recent clients/collaborators for regulatory/pharmaceutical development support.
Beyond the preview
Go deeper on NeuGATE Theranostics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeuGATE Theranostics.